Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

Fig. 1

Sensitivity of prostate cancer cells or non-malignant prostate epithelial cells to SAHA or veliparib-induced cell killing. LNCaP, C4–2, DU145, VCaP, PC-3 and CWR22Rv1 PCa cells and non-malignant RWPE-1 prostate epithelial cells were treated with SAHA (a) or veliparib (b) at increasing concentrations as shown. Cells were stained with crystal violet 3 days after treatment and then lysed with 1% SDS. Cell viability was measured by spectrometer as OD570 nm. Graph represents the mean cell viability ± SD of 3 independent experiments. c The protein levels of BRCA1 and BRCA2 were assessed by western blot in PCa cells and non-malignant RWPE-1 prostate epithelial cells

Back to article page